Paslay Consulting Group, Seattle, WA, USA
5th HTRF Symposium, Avignon, France
During the last thirty years high throughput screening (HTS) has evolved from an emerging technology to a mature, multicomponent toolset. The use of HTS in the biopharmaceutical industry has spread from its roots in hit identification through the entire drug discovery and early development process. Applications of HTS approaches have migrated from human to animal health, from life sciences to material sciences, and from industry to academia. It has been a key driver in significant technological advancements in instruments, reagents, and services that have enabled HTSs growth and productivity. Where will HTS go from here? Challenges in the biopharmaceutical industry, original home of HTS, have focused evaluation of this technologys impact and necessity as an internally maintained core skill. Additionally, emerging alternative approaches for human therapy such as patient-specific therapies, regenerative medicine, biotic devices and nanotechnology are all changing the discovery and development paradigm. For practitioners it is easy to envision how the breadth of HTS skills and tools can impact these emerging areas, but future expansion and advancement of HTS requires demonstration of successful integration in this changing environment.